MISSION WOODS, Kan., Jan. 17, 2024 /PRNewswire/ — Palmer Square Capital BDC Inc. (“Palmer Square“), an externally managed business development company, today announced that it priced its initial public offering of 5,450,000 shares of its common stock at $16.45 per share, for anticipated gross proceeds of approximately $89.7 million. Palmer Square’s shares of common stock… Continue reading Palmer Square Capital BDC Inc. Prices Initial Public Offering
Tag: Morgan
Talos Energy Announces Commencement of Underwritten Public Offering of Common Stock
HOUSTON, Jan. 17, 2024 /PRNewswire/ — Talos Energy Inc. (“Talos” or the “Company”) (NYSE: TALO) today announced that it has commenced an underwritten public offering of $300.0 million of shares of its common stock, par value $0.01 per share (“common stock”). The Company expects to grant the underwriters a 30-day option to purchase $45.0 million… Continue reading Talos Energy Announces Commencement of Underwritten Public Offering of Common Stock
Scientists Fascinated by Extremely Muscular 93-Year-Old Man
Image by Getty / Futurism An elderly Irish man is so fit that he’s become the subject of a case study — and for those who aren’t exercising regularly, take hope: he didn’t start working out until he was in his 70s. As the Washington Post reports, doctors say 93-year-old indoor rowing champion Richard Morgan has the… Continue reading Scientists Fascinated by Extremely Muscular 93-Year-Old Man
Kura Labs Accelerates Growth With Donation From MacKenzie Scott
Funding Will Contribute to the Expansion of Free Training and Job Placement For Underserved Communities Across Cloud Infrastructure, DevOps, Data Engineering, AI Infrastructure, and Cybersecurity NEW YORK, Jan. 17, 2024 /PRNewswire/ — Kura Labs, a leading cloud infrastructure computing training and job placement non-profit academy for underserved communities, today announced a donation from philanthropist MacKenzie Scott.… Continue reading Kura Labs Accelerates Growth With Donation From MacKenzie Scott
Extra Space Announces Pricing of $600 Million of 5.400% Senior Notes due 2034
SALT LAKE CITY, Jan. 16, 2024 /PRNewswire/ — Extra Space Storage Inc. (“Extra Space”) (NYSE: EXR), a leading owner and operator of self-storage facilities in the United States and a member of the S&P 500, today announced that its operating partnership, Extra Space Storage LP (the “operating partnership”), has priced a public offering of $600… Continue reading Extra Space Announces Pricing of $600 Million of 5.400% Senior Notes due 2034
Blue Owl Capital Corporation III Announces Intention to List on the New York Stock Exchange
NEW YORK, Jan. 16, 2024 /PRNewswire/ — Blue Owl Capital Corporation III (“OBDE” or the “Company”), a leading business development company (“BDC”) focused on lending to U.S. upper middle-market companies, announced today that it intends to list the Company’s shares of common stock on the New York Stock Exchange (“NYSE”). Subject to market conditions, the… Continue reading Blue Owl Capital Corporation III Announces Intention to List on the New York Stock Exchange
Valo Health Announces Changes to its Board of Directors and Leadership Team
Appoints Christian Schade as Executive Chairman and Graeme Bell as Interim CEO BOSTON, Jan. 16, 2024 /PRNewswire/ — Valo Health, Inc (“Valo”), a technology company focused on utilizing large scale data and artificial intelligence (“AI”) driven computation to discover and develop therapeutics, today announced the appointment of Christian Schade as the newly-created role of Executive Chairman of the… Continue reading Valo Health Announces Changes to its Board of Directors and Leadership Team
Around 40% of firms on top Tokyo bourse disclose capital efficiency plansAnother 9% are considering such measures.
Nearly half of the companies on the Tokyo Stock Exchange’s (TSE) prime section have responded to a call to disclose plans to improve capital efficiency, the bourse said on Monday, as it released for the first time a list of those who had complied. The list, which did not include some of Japan’s biggest and most influential companies such… Continue reading Around 40% of firms on top Tokyo bourse disclose capital efficiency plansAnother 9% are considering such measures.
Darmiyan 首個用於預測阿茲海默症發展可能性的預後測試 BrainSee 獲 FDA 許可
美國食品藥物管理局 (FDA) 對 BrainSee 的 De Novo 上市許可標誌著阿茲海默症診斷的一大進步。BrainSee 憑藉先進的影像處理和醫療人工智能技術，為從遺忘型輕度認知功能障礙 (aMCI) 發展成阿茲海默症的可能性預測樹立了新標準。這一突破是主動腦部健康管理的重要一步，提供了完全非入侵性、方便、全球通用的篩查方案，能夠優先在其他測試或治療之前展開。 三藩市2024年1月15日 /美通社/ — 今天，領先的腦部健康創新公司 Darmiyan, Inc. 宣佈，其首創 BrainSee 的臨床測試 (De Novo) 獲得 FDA 的許可，為對抗阿茲海默症的戰役帶來了關鍵的轉捩點。獲此許可意味著腦部健康領域有的重大進展，同時也擴闊了腦部健康診斷和管理方面尚未開發的市場潛力。 BrainSee 以 40 多年的領先腦部科學為基礎，採用先進的全腦影像分析和醫療人工智能技術，是 Darmiyan 核心專利技術的首個臨床應用。它是一個可擴展性高且完全自動化的軟件平台，結合了標準臨床腦部 MRI 認知評估（這是對記憶力衰退患者的常規非入侵性檢查的一部分），並能夠生成客觀評分，預測患者在 5 年內從 aMCI 發展成阿茲海默症的可能性。BrainSee 填補了逾 1000 万美國人以及全球逾 1 億位正在與 aMCI 抗爭的患者们未被滿足的關鍵需求。隨著全球人口老齡化，預計 BrainSee 的社會經濟影響力將快速和急劇增長。 Continue Reading Darmiyan Darmiyan 創辦人兼行政總裁 Padideh Kamali-Zare 博士表示：「我們的願景是重新定義腦部健康篩查和監測的標準，並以有意義的方式改變患者及其家庭成員的生活。BrainSee 是在這個願景下誕生的首個產品，由我們可信賴的技術基礎設施支援，能夠進一步推動腦部健康領域的轉型和可擴展創新。」… Continue reading Darmiyan 首個用於預測阿茲海默症發展可能性的預後測試 BrainSee 獲 FDA 許可
Darmiyan获得FDA对BrainSee的批准，这是首个能够预测阿尔茨海默病痴呆症发展可能性的预后测试
美国食品药物管理局 (FDA) 对 BrainSee 的 De Novo 批准代表了在阿尔兹海默症诊断上的重大进步。BrainSee 采用了先进的图像处理技术并由医学人工智能提供支持，为从遗忘型轻度认知障碍 (aMCI) 发展到阿尔茨海默病痴呆的可能性设立了新的预测标准。本次突破是主动大脑健康管理的重要一步，提供了全面的非侵入性、便捷且全球适用的筛查解决方案，值得在其他测试和治疗前优先考虑。 旧金山 2024年1月15日 /美通社/ — 今天标志着 Darmiyan, Inc. 对抗阿尔兹海默症取得转折点式成绩，这家领先的脑类医疗创新公司宣布，FDA 已批准了其首款同类产品 BrainSee 的临床测试 (De Novo)。这一批准标志着脑健康领域的一项重大进展，并为尚且无人涉足，但充满潜力的脑类疾病诊断和管理的市场打开了大门。 BrainSee 是首款采用 Darmiyan 专利核心技术的临床应用，该应用基于该公司所累积的逾 40 年先进的大脑科学，并采用高级全脑成像分析技术，由医学人工智能提供支持。这是一款扩展性极强且完全自动化的软件平台，结合标准临床大脑 MRI 和认知分析，即对失忆患者进行常规非侵入性检查，并能得出一个客观评分，预测患者 5 年内从 aMCI 发展为阿尔茨海默痴呆症的可能性。BrainSee 解决了饱受 aMCI 困扰的 1000 万美国人和全球 1 亿患者面临的迫切需求。随着全球人口的老化，BrainSee 的社会经济影响预计也将快速并呈指数级增长。 Continue Reading Logo Darmiyan 创始人兼行政总裁 Padideh Kamali-Zare 博士表示：”我们的愿望是重新定义大脑健康的筛查和监测标准，并为患者及其家人们的生活带去更有意义的影响。BrainSee 是该愿景下的首款产品，在我们坚实的技术基础设施支持下，将进一步推动大脑医疗健康未来的转型和大规模创新。” BrainSee 的早期筛查和风险评估，能够为那些发展为阿尔茨海默氏痴呆症的高危 aMCI… Continue reading Darmiyan获得FDA对BrainSee的批准，这是首个能够预测阿尔茨海默病痴呆症发展可能性的预后测试